BridgeBio Pharma Inc

On February 21, 2024, we, through BridgeBio Services, Inc. (the “Services Company”), entered into an amendment (the “Amendment”) to the employment agreement of Dr. Brian Stephenson, our Chief Financial Officer and Secretary. The Amendment provides the following: (i) in the event of a termination of his employment by the Services Company without “cause” or Dr. Stephenson’s resignation from employment with the Services Company for “good reason,” Dr. Stephenson will be entitled to the following severance payments and benefits: (a) a lump sum payment equal to 9 months of his then-current base salary; and (b) up to 9 months of COBRA reimbursements; and (ii) in the event of a termination of his employment by the Services Company without “cause” or Dr. Stephenson’s resignation from employment with the Services Company for “good reason” upon or within 12 months after a “sale event,” Dr. Stephenson will be entitled to the following severance payments and benefits: (a) a lump sum payment equal to 12 months of his then-current base salary; (b) his then annual target bonus; and (c) up to 12 months of COBRA reimbursements. In each case, Dr. Stephenson is entitled to receive such severance payments and benefits subject to his execution of an effective release of claims in favor of the Services Company. The terms “good reason,” “cause” and “sale event” are as defined in the Amendment.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed herewith as Exhibit 10.39 and incorporated herein by reference.